IP Library › Patent Application 11561825
Patent Application
App. No. 11/561,825

COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/561,825
Abstract

Pharmaceutical compositions comprising a PYY peptide, a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.

Claims (13)

1 . A pharmaceutical composition comprising a PYY peptide, a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.

2 . The pharmaceutical composition of claim 1 , wherein the PYY peptide is PYY (3-36).

3 . The pharmaceutical composition of claim 1 , wherein the phosphatidylcholine is L-α-phosphatidylcholine didecanoyl (DDPC).

4 . The pharmaceutical composition of claim 1 , wherein the cyclodextrin is selected from the group consisting of hydroxypropyl-α-cyclodextrin, sulfobutylether-β-cyclodextrin, and methyl-β-cyclodextrin.

5 . The pharmaceutical composition of claim 1 , wherein the cyclodextrin is methyl-β-cyclodextrin.

6 . The pharmaceutical composition of claim 1 , wherein the composition is an aqueous composition having a pH of from about 3 to about 6.

7 . The pharmaceutical composition of claim 13 , wherein the pH is 5.0±0.5.

8 . The pharmaceutical composition of claim 1 , further comprising a polyol.

9 . The pharmaceutical composition of claim 8 , wherein the polyol is selected from the group consisting of sucrose, mannitol, sorbitol, lactose, L-arabinose, D-erythrose, D-ribose, D-xylose, D-mannose, trehalose, D-galactose, lactulose, cellobiose, gentibiose, glycerin and polyethylene glycol.

10 . The pharmaceutical composition of claim 8 , wherein the polyol is sorbitol.

11 . The pharmaceutical composition of claim 8 , further comprising a chelating agent.

12 . The pharmaceutical composition of claim 11 , wherein the chelating agent is ethylene diamine tetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA).

13 . The pharmaceutical composition of claim 11 , wherein the chelating agent is ethylene diamine tetraacetic acid (EDTA).